Opko Health (OPK) AI Stock Analysis

• Market Cap: $1.05B
• Dividend Yield: N/A
• Average Volume (3M): 3.16M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.88
• Revenue Growth: -13.79%
• EPS Growth: 82.82%
• Country: US
• Employees: 2,997
• Sector: Healthcare
• Sector Strength: 47
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.10
• Shares Outstanding: 793,052,800
• 10 Day Avg. Volume: 4,589,407
• 30 Day Avg. Volume: 3,158,910
• PEG Ratio: -0.88
• Price to Book (P/B): 0.66
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.96
• Enterprise Value/Market Cap: 1.02
• Enterprise Value/Revenue: 0.38
• Enterprise Value/Gross Profit: 4.93
• Enterprise Value/Ebitda: 5.84
• 1Y Price Target: $2.75
• Price Target Upside: 105.22% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 52 Neutral
• Price Target: $1.50 ▲(11.94%Upside)

Opko Health faces substantial financial challenges with negative profitability and cash flow metrics as significant risk factors. Strategic initiatives and R&D developments offer some optimism, but are insufficient to offset the negative financial and valuation outlook.

Positive Factors

Cost-Saving Measures

OPKO has identified additional cost-saving measures, targeting $10 million in annualized cost reductions.

Diagnostics Segment Improvement

OPKO Health's diagnostics segment showed a significant improvement, with a reduction in operating losses compared to the previous year.

Partnership and Strategic Alliances

OPKO entered an agreement with Labcorp for Labcorp to acquire laboratory testing businesses focused on oncology and oncology-related clinical testing services across the U.S. from BioReference Health, a wholly owned subsidiary of OPKO.

Negative Factors

Reduced Financial Guidance

Management slightly reduced certain elements of its financial guidance for the fiscal year, including total revenue and NGENLA gross profit share.

Revenue Decline

Total revenue was $149.9M, representing 13.7% YoY decline and missing our projection of $162.5M.

Weaker Financial Performance

OPKO Health delivered a somewhat weaker-than-expected Q1 result, with revenue and EPS falling short of estimates.

Opko Health Business Overview & Revenue Model

Company Description

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

How the Company Makes Money

OPKO Health generates revenue through several streams. One significant source is its diagnostics business, which includes clinical laboratories and diagnostic testing services. The company also earns income from its pharmaceuticals segment by developing, manufacturing, and selling prescription medications and biologics. Additionally, OPKO Health engages in licensing agreements and strategic partnerships to further monetize its intellectual property and expand its market reach. Key partnerships and collaborations with other healthcare and pharmaceutical companies also contribute to its revenue, providing opportunities for shared research, development, and commercialization of healthcare solutions.

Opko Health Financial Statement Overview

Summary

Opko Health's financial performance is challenged by declining revenue and negative profitability metrics. Despite improvements in operational efficiency, significant issues like negative net income and free cash flow indicate ongoing financial difficulties. A solid equity base provides some financial stability.

Income Statement

Opko Health's TTM (Trailing-Twelve-Months) results show a decline in revenue along with negative EBIT and net income, indicating profitability challenges. The gross profit margin is 32.12%, and the net profit margin is -5.66%, reflecting difficulties in maintaining profitability. Revenue has decreased by 23.34% from 2022 to 2023, highlighting a concerning trend. However, the EBITDA margin of 17.07% shows some operational efficiency improvement.

Balance Sheet

The company's debt-to-equity ratio stands at 0.37, indicating moderate leverage. The return on equity is negative, given the negative net income, suggesting inefficiencies in using equity capital. The equity ratio of 61.64% shows a solid equity base relative to total assets, which can be seen as a financial stability buffer.

Cash Flow

Opko Health's cash flow performance reflects operational challenges, with a negative free cash flow of -$206.24 million in the TTM. The operating cash flow to net income ratio is negative, which indicates that cash flow from operations is not supporting net income. The free cash flow to net income ratio is also negative, suggesting strained cash generation relative to earnings.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	689.41M	713.14M	863.50M	1.00B	1.77B	1.44B
Gross Profit	219.06M	218.51M	318.13M	288.20M	672.55M	541.00M
EBITDA	150.45M	135.28M	-65.52M	-270.81M	83.57M	139.09M
Net Income	-39.00M	-53.22M	-188.86M	-328.40M	-30.14M	30.59M
Balance Sheet
Total Assets	2.13B	2.20B	2.01B	2.17B	2.40B	2.47B
Cash, Cash Equivalents and Short-Term Investments	436.00M	431.94M	95.88M	153.20M	134.70M	72.20M
Total Debt	492.89M	504.44M	326.56M	213.50M	187.90M	222.00M
Total Liabilities	816.66M	834.76M	622.48M	605.70M	714.60M	801.50M
Stockholders Equity	1.31B	1.37B	1.39B	1.56B	1.69B	1.67B
Cash Flow
Free Cash Flow	-206.24M	-208.50M	-44.47M	-119.77M	6.18M	5.79M
Operating Cash Flow	-182.48M	-183.49M	-28.20M	-95.19M	38.34M	39.48M
Investing Cash Flow	397.14M	352.21M	-18.20M	91.04M	35.95M	-18.33M
Financing Cash Flow	159.53M	184.17M	-11.30M	22.97M	-10.35M	-35.08M

Opko Health Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.34
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OPK, the sentiment is Neutral. The current price of 1.34 is above the 20-day moving average (MA) of 1.33, above the 50-day MA of 1.33, and below the 200-day MA of 1.51, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 52.87 is Neutral, neither overbought nor oversold. The STOCH value of 79.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for OPK.

Opko Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CDNA	74 Outperform	$1.05B	16.92	21.57%	―	25.92%	―
CSTL	73 Outperform	$587.26M	30.59	-1.20%	―	38.43%	86.19%
OPK	52 Neutral	$1.05B	―	-3.04%	―	-13.79%	82.82%
Sector *	51 Neutral	$7.55B	0.30	-61.90%	2.27%	17.11%	1.58%
NEO	51 Neutral	$953.63M	―	-8.57%	―	10.10%	8.79%
NEOG	45 Neutral	$1.10B	―	-16.71%	―	-2.50%	-30760.27%
MYGN	45 Neutral	$518.96M	―	-13.84%	―	7.38%	60.45%

Opko Health Corporate Events

Opko Health Grants Stock Options and Bonuses

On May 27, 2025, Opko Health‘s Compensation Committee granted stock options and approved bonuses for its executive officers and non-executive employees. This decision reflects the company’s commitment to incentivizing its leadership and workforce, potentially impacting its operational efficiency and stakeholder confidence.

The most recent analyst rating on (OPK) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Opko Health stock, see the OPK Stock Forecast page.